Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBLN
CUSIPN/A
Phone760-795-6558
Debt
Debt-to-Equity Ratio0.29
Current Ratio4.29
Quick Ratio4.09
Price-To-Earnings
Trailing P/E Ratio-1.00
Forward P/E Ratio-0.96
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.91 million
Price / Sales3.74
Cash FlowN/A
Price / CashN/A
Book Value$1.54 per share
Price / Book1.37
Profitability
EPS (Most Recent Fiscal Year)($2.08)
Net Income$-34,760,000.00
Net Margins-399.94%
Return on Equity-102.17%
Return on Assets-71.95%
Miscellaneous
Employees113
Outstanding Shares17,570,000
Market Cap$38.66
Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions
What is Obalon Therapeutics' stock symbol?
Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."
How were Obalon Therapeutics' earnings last quarter?
Obalon Therapeutics Inc (NASDAQ:OBLN) posted its earnings results on Monday, March, 5th. The company reported ($0.60) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.12. The firm had revenue of $3.69 million for the quarter, compared to analysts' expectations of $3.88 million. Obalon Therapeutics had a negative net margin of 399.94% and a negative return on equity of 102.17%. View Obalon Therapeutics' Earnings History.
When is Obalon Therapeutics' next earnings date?
What price target have analysts set for OBLN?
5 Wall Street analysts have issued 1-year price objectives for Obalon Therapeutics' shares. Their forecasts range from $4.00 to $16.00. On average, they anticipate Obalon Therapeutics' stock price to reach $9.25 in the next twelve months. This suggests a possible upside of 338.4% from the stock's current price. View Analyst Ratings for Obalon Therapeutics.
What is the consensus analysts' recommendation for Obalon Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Obalon Therapeutics stock?
Here are some recent quotes from research analysts about Obalon Therapeutics stock:
- 1. According to Zacks Investment Research, "Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company's product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. " (7/11/2018)
- 2. Northland Securities analysts commented, "We have reached out to management, but have not heard back yet. As we have said multiple times in our notes, we are persona non grata with the company, hence are not hopeful that we can have adequate answers to our questions, which are: What specifically is the allegation? Is it about channel stuffing? Is it about revenue recognition? As highlighted in our Dec 6, 2017 research note, we had questions about Obalon’s revenue recognition criteria, and how the accounting for deliverables was being done. A key question for us is…who knew what & when? Is there any truth to the whistleblower allegations, whatever they may be? As a reminder, Obalon’s new marketing program was implemented at start of Q4-17." (1/23/2018)
Who are some of Obalon Therapeutics' key competitors?
Some companies that are related to Obalon Therapeutics include Motus GI (MOTS), Sensus Healthcare (SRTS), Invuity (IVTY), Restoration Robotics (HAIR), Alphatec (ATEC), Invo Bioscience (IVOB), Neovasc (NVCN), Arch Therapeutics (ARTH), Spectral Medical (EDTXF), CAS Medical Systems (CASM), SANUWAVE Health, Inc. Common Stock (SNWV), iCAD (ICAD), Repro-Med Systems (REPR), Nephros (NEPH) and Valeritas (VLRX).
Who are Obalon Therapeutics' key executives?
Obalon Therapeutics' management team includes the folowing people:
- Mr. Andrew P. Rasdal, Pres, CEO & Director (Age 60)
- Mr. William John Plovanic CFA, CFO & Sec. (Age 49)
- Mr. Mark C. Brister, Chief Technology Officer (Age 56)
- Dr. Kelly Huang Ph.D., Chief Operating Officer (Age 49)
- Ms. Nooshin Hussainy, VP of Fin. & Principal Accounting Officer (Age 60)
When did Obalon Therapeutics IPO?
(OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.
Has Obalon Therapeutics been receiving favorable news coverage?
Media stories about OBLN stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Obalon Therapeutics earned a news sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the company an impact score of 45.76 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Obalon Therapeutics?
Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Obalon Therapeutics' stock price today?
One share of OBLN stock can currently be purchased for approximately $2.11.
How big of a company is Obalon Therapeutics?
Obalon Therapeutics has a market capitalization of $38.66 million and generates $9.91 million in revenue each year. The company earns $-34,760,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Obalon Therapeutics employs 113 workers across the globe.
How can I contact Obalon Therapeutics?
Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 760-795-6558 or via email at [email protected]
MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
